top of page

Free Biopharma Daily Stock Updates - 07/01/22

$XBI $76.54 | +3.06%

BiopharmIQ offers pro members full access to FDA Catalyst Calendar, PDUFA's, Biotech Stock Ideas.


Table of Contents:


Covid Updates

#NVAX +11.1% Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA. source


#NRXP -6.3% FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir. source


Pipeline Updates

#ENDP +22.4% Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder. source


#BCRX +2.5% BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat). source


#ICPT +2.3% Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S. source


#SRRK -2.9% Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022). source


#BMEA -6.9% Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes. source

 

Want to get weekly catalyst updates?

*We never spam you - unsubscribe anytime*

 

Business Updates

#ENDP +22.4% Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor. source


#CYTK +4.4% CYTOKINETICS ANNOUNCES PRICING OF $450 MILLION CONVERTIBLE SENIOR NOTES OFFERING. source


#AGRX -45.0% AGILE THERAPEUTICS ANNOUNCES PRICING OF $24 MILLION UPSIZED PUBLIC OFFERING. source

 

Posted by DV/FS

0 comments
bottom of page